Active Trials

Breast Cancer 

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative  Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score  ≤ 18 Breast Cancer 

Summary: 

This study is for patients age 50-70, who have been diagnosed with early stage breast  cancer who have had breast-conserving surgery also known as lumpectomy, with an  Oncotype Recurrence Score equal to or less than 18 and is sensitive to hormones. The  study compares the usual approach after lumpectomy to the use of hormonal drugs  alone. This study will allow researchers to know whether treatment with hormonal drugs  alone is better, the same or worse than the usual approach. 

For more information: https://clinicaltrials.gov/ct2/show/NCT04852887 

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors:  A Multi-Center Randomized Double-Blinded Controlled Trial 

Summary: 

This goal of this trial is to determine the efficacy of advanced cognitive training for  cancer survivors suffering from cancer and cancer-treatment-related cognitive  dysfunction.  

For more information: https://clinicaltrials.gov/study/NCT05896189?term=NRG CC011&rank=1 

Harnessing E-Mindfulness Approaches for Living-After Breast Cancer –HEAL-ABC 

Summary: 

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy  of two distinct digital approaches for delivering a mindfulness-based intervention: a live,  instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced  version (MAPs App). Participants will include younger breast cancer survivors (BCS)  who were diagnosed with breast cancer at or before age 50 years, have completed their  primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6  months earlier, and report elevated depressive symptoms. 

For more information: https://clinicaltrials.gov/study/NCT06748222

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node Positive, Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer with High  Risk of Recurrence- A Global, Multicenter, Randomized, Open-Label Phase 3 Study  (ELEGANT) 

Summary: 

The primary goal of this study is to evaluate the effectiveness of elacestrant versus  standard endocrine therapy in participants with node-positive, Estrogen Receptor positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast  cancer with high risk of recurrence. 

For more information: https://clinicaltrials.gov/study/NCT06492616 

Colon Cancer 

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE US) 

Summary: 

This phase II/III study is for patients with stage III and high risk stage II colon cancer.  The study will be seeking to determine whether chemotherapy is needed for all or only  some patients in this population, and, if chemotherapy is needed, what kind of  chemotherapy to recommend to patients based on the presence or absence of  circulating tumor DNA (ctDNA) following surgery for colon cancer. 

For more information: https://clinicaltrials.gov/study/NCT05174169 

Lung Cancer 

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab  versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with  Metastatic EGFR- Mutant Non-Small Cell Lung Cancer (NSCLC) 

Summary: 

A phase III study for patients who have been diagnosed with non-small lung cancer that  has spread outside of the lungs and has a change in a gene called EGFR. The study  compares the usual treatment approach of osimertinib alone to using bevacizumab plus  osimertinib. This study will help researchers know whether this new approach of  bevacizumab plus osimertinib is better, the same or worse than the usual approach. 

For More Information: https://clinicaltrials.gov/ct2/show/NCT04181060

Prostate Cancer 

The Phase III ‘High Five Trial’ Five Fraction Radiation for High-Risk Prostate Cancer 

Summary: 

This phase III trial compares stereotactic body radiation therapy (SBRT), (five  treatments over two weeks using a higher dose per treatment) to usual radiation therapy  (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer.  SBRT uses special equipment to position a patient and deliver radiation to tumors with  high precision. This method may kill tumor cells with fewer doses over a shorter period  of time. This trial is evaluating if shorter duration radiation prevents cancer from coming  back as well as the usual radiation treatment. 

For More Information: https://clinicaltrials.gov/study/NCT05946213